© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective
aMedical University of South Carolina, Charleston, SC, USA
bWinters Center for Heart Failure Research, Section of Cardiology, Houston VAMC and Baylor College of Medicine, Houston, TX, USA
* Corresponding author. Cardiothoracic Surgery, Room 625, Strom Thurmond Research Building, 770 MUSC Complex, Medical University of South Carolina, 114 Doughty Street, Charleston, SC 29425, USA. Tel.: +1-843-876-5184; fax: +1-843-876-5187
A milestone in the progression of congestive heart failure (CHF) is myocardial remodeling. Left ventricular (LV) remodeling during the progression of CHF is accompanied by changes in the structure of the myocardial extracellular matrix. Recent clinical and experimental studies have noted that increased release of tumor necrosis factor alpha (TNF-
) can contribute to LV myocardial remodeling. Experimental studies have noted that the induction of TNF- can result in LV dilation and proceed to LV pump dysfunction. The biological effects of TNF- are mediated through TNF receptors that are present on all nucleated cells in the heart. TNF receptor activation can induce a number of cellular and molecular events which contribute to LV remodeling in CHF, and include changes in myocyte size and viability and alterations in myocardial structure/composition. In vitro studies have demonstrated that TNF receptor activation can cause the induction of a proteolytic system. This proteolytic system, the matrix metalloproteinases (MMPs), is upregulated in models of LV dysfunction and possesses the capacity to degrade a wide variety of extracellular matrix components. Therefore, one pathway by which TNF- can influence LV myocardial remodeling is through the induction of a specific portfolio of MMP species. Future basic and clinical studies which directly alter TNF receptor activity and measure myocardial MMP species and the relation to LV remodeling will provide new insight into this disease process and future therapeutic modalities.
KEYWORDS AP-1, Activating protein 1; CHF, Congestive heart failure; ECM, Extracellular matrix; LV, Left ventricle; LVEF, Left ventricular ejection fraction; MMP, Matrix metalloproteinase; MRI, Magnetic resonance imaging; NF-
B, Nuclear factor kappa B; NYHA, New York Heart Association; TNF-, Tumor necrosis factor alpha; TNFR1, Tumor necrosis factor alpha receptor type 1; TNFR2, Tumor necrosis factor alpha receptor type 2
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Palanivel, V. Vu, M. Park, X. Fang, and G. Sweeney Differential impact of adipokines derived from primary adipocytes of wild-type versus streptozotocin-induced diabetic rats on glucose and fatty acid metabolism in cardiomyocytes J. Endocrinol., December 1, 2008; 199(3): 389 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wang, P. R. Crisostomo, T. A. Markel, Y. Wang, and D. R. Meldrum Mechanisms of Sex Differences in TNFR2-Mediated Cardioprotection Circulation, September 30, 2008; 118(14_suppl_1): S38 - S45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Bucciarelli, R. Ananthakrishnan, Y. C. Hwang, M. Kaneko, F. Song, D. R. Sell, C. Strauch, V. M. Monnier, S. F. Yan, A. M. Schmidt, et al. RAGE and Modulation of Ischemic Injury in the Diabetic Myocardium Diabetes, July 1, 2008; 57(7): 1941 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mariappan, R. N. Soorappan, M. Haque, S. Sriramula, and J. Francis TNF-{alpha}-induced mitochondrial oxidative stress and cardiac dysfunction: restoration by superoxide dismutase mimetic Tempol Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2726 - H2737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsujita, K. Kaikita, T. Hayasaki, T. Honda, H. Kobayashi, N. Sakashita, H. Suzuki, T. Kodama, H. Ogawa, and M. Takeya Targeted Deletion of Class A Macrophage Scavenger Receptor Increases the Risk of Cardiac Rupture After Experimental Myocardial Infarction Circulation, April 10, 2007; 115(14): 1904 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Takimoto and D. A. Kass Role of Oxidative Stress in Cardiac Hypertrophy and Remodeling Hypertension, February 1, 2007; 49(2): 241 - 248. [Full Text] [PDF]
|
|
|
|
|
|
K. W. Lee, T. H. Everett IV, D. Rahmutula, J. M. Guerra, E. Wilson, C. Ding, and J. E. Olgin Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure Circulation, October 17, 2006; 114(16): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W.M. Fedak, C. S. Moravec, P. M. McCarthy, S. M. Altamentova, A. P. Wong, M. Skrtic, S. Verma, R. D. Weisel, and R.-K. Li Altered Expression of Disintegrin Metalloproteinases and Their Inhibitor in Human Dilated Cardiomyopathy Circulation, January 17, 2006; 113(2): 238 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Miner and W. L. Miller A Look Between the Cardiomyocytes: The Extracellular Matrix in Heart Failure Mayo Clin. Proc., January 1, 2006; 81(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gurantz, A. Yndestad, B. Halvorsen, O. V. Lunde, J. H. Omens, T. Ueland, P. Aukrust, C. D. Moore, J. Kjekshus, and B. H. Greenberg Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling Cardiovasc Res, July 1, 2005; 67(1): 106 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Prabhu Cytokine-Induced Modulation of Cardiac Function Circ. Res., December 10, 2004; 95(12): 1140 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sun, F. Dawood, W.-H. Wen, M. Chen, I. Dixon, L. A. Kirshenbaum, and P. P. Liu Excessive Tumor Necrosis Factor Activation After Infarction Contributes to Susceptibility of Myocardial Rupture and Left Ventricular Dysfunction Circulation, November 16, 2004; 110(20): 3221 - 3228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W.M. Fedak, D. S. Smookler, Z. Kassiri, N. Ohno, K. J. Leco, S. Verma, D. A.G. Mickle, K. L. Watson, C. V. Hojilla, W. Cruz, et al. TIMP-3 Deficiency Leads to Dilated Cardiomyopathy Circulation, October 19, 2004; 110(16): 2401 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakano, S. Niida, K. Dote, S. Takenaka, H. Hirao, F. Miura, M. Ishida, T. Shingu, T. Sueda, M. Yoshizumi, et al. Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation J. Am. Coll. Cardiol., March 3, 2004; 43(5): 818 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, and J. T. Willerson Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-{alpha}, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial Circulation, July 1, 2003; 107(25): 3133 - 3140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. M. Fedak, S. M. Altamentova, R. D. Weisel, N. Nili, N. Ohno, S. Verma, T.-Y. J. Lee, C. Kiani, D. A. G. Mickle, B. H. Strauss, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3 Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H626 - H634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsuruda, G. Boerrigter, B. K. Huntley, J. A. Noser, A. Cataliotti, L. C. Costello-Boerrigter, H. H. Chen, and J. C. Burnett Jr Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases Circ. Res., December 13, 2002; 91(12): 1127 - 1134. [Abstract] [Full Text] [PDF]
|
|